UK markets close in 3 hours 52 minutes

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.96+0.74 (+5.20%)
At close: 04:00PM EDT
14.96 +0.00 (+0.01%)
Pre-market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close14.22
Open14.33
Bid14.96 x 100
Ask15.02 x 400
Day's range14.30 - 14.98
52-week range4.29 - 21.88
Volume900,505
Avg. volume1,403,937
Market cap933.983M
Beta (5Y monthly)2.10
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

    Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical comp

  • GlobeNewswire

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024: TD Cowen’s 44th Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., wil

  • GlobeNewswire

    MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

    ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursda